EDMONTON, ALBERTA--(Marketwire - Feb. 20, 2008) - CV Technologies Inc. (TSX:CVQ) today announced positive safety results in a pilot clinical trial as the first step in developing a children’s formulation of COLD-fX® - the # 1 selling cold and flu remedy in Canada.
